YU72303A - Postupak za dobijanje (-)-4-amino-5-fluoro-1- (2-hiroksimetil-1,3-oksatiolan-5-il)-(1h)-pirimidin-2-ona - Google Patents

Postupak za dobijanje (-)-4-amino-5-fluoro-1- (2-hiroksimetil-1,3-oksatiolan-5-il)-(1h)-pirimidin-2-ona

Info

Publication number
YU72303A
YU72303A YU72303A YU72303A YU72303A YU 72303 A YU72303 A YU 72303A YU 72303 A YU72303 A YU 72303A YU 72303 A YU72303 A YU 72303A YU 72303 A YU72303 A YU 72303A
Authority
YU
Yugoslavia
Prior art keywords
oxatiolan
pyrmidine
hydroxymethyl
fluoro
amino
Prior art date
Application number
YU72303A
Other languages
English (en)
Inventor
Gervais Dionne
Original Assignee
Shire Biochem Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10699340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU72303(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Biochem Inc. filed Critical Shire Biochem Inc.
Publication of YU72303A publication Critical patent/YU72303A/sh
Publication of RS49993B publication Critical patent/RS49993B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/167—Heterorings having sulfur atoms as ring heteroatoms, e.g. vitamin B1, thiamine nucleus and open chain analogs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/38—Nucleosides
    • C12P19/40—Nucleosides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same ring, e.g. purine nucleosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/001—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by metabolizing one of the enantiomers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/006—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Ovaj pronalazak se prvenstveno odnosi na postupak dobijanja (-)-4-amino-5-fluoro-1-(2-hidroksimetil-1,3-oksatiolan-5-il)-(1H)-pirimidin-2-ona i njegovih farmaceutski prihvatljivih derivata iz racemske smeše jedinjenja pomoću hiralnog HPLC-a, korišćenjem enzimskog enantioselektivnog katabolizma. Na ovaj način dobija se pomenuti (-) enantiomer koji je suštinski čist ili sadrži (+) enentiomer u količini ne većoj od 1 do 5%.[Invention herewith described primarily refers to the procedure for obtaining (-)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxatiolan-5-yl)- (1H)-pyrmidine-2-on and its pharmaceutically acceptable derivatives from raceme composition of compounds by means of chiral HPLC, using enzyme enanthioselective catabolism. In this way the mentioned (-) enenthiomer that is essentially pure or contains (+) enentiomer in the amount not more than 1 to 5 %.
YUP-723/03A 1991-08-01 1992-07-31 Postupak za dobijanje (-)-4-amino-5-fluoro-1-(2-hidroksimetil-1,3-oksatiolan-5-il)-(1h)-pirimidin-2-ona RS49993B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919116601A GB9116601D0 (en) 1991-08-01 1991-08-01 1,3-oxathiolane nucleoside analogues

Publications (2)

Publication Number Publication Date
YU72303A true YU72303A (sh) 2006-05-25
RS49993B RS49993B (sr) 2008-09-29

Family

ID=10699340

Family Applications (1)

Application Number Title Priority Date Filing Date
YU74992A YU49259B (sh) 1991-08-01 1992-07-31 (-)-4-amino-5 fluoro-1-(2-hidroksimetil-1,3-oksatiolan-5-il)-(1h)-pirimidin-2-on

Family Applications Before (1)

Application Number Title Priority Date Filing Date
YU74992A YU49259B (sh) 1991-08-01 1992-07-31 (-)-4-amino-5 fluoro-1-(2-hidroksimetil-1,3-oksatiolan-5-il)-(1h)-pirimidin-2-on

Country Status (41)

Country Link
US (2) US5538975A (sh)
EP (2) EP1155695B1 (sh)
JP (1) JP2960778B2 (sh)
KR (1) KR100242454B1 (sh)
CN (5) CN1034810C (sh)
AP (1) AP321A (sh)
AT (2) ATE227720T1 (sh)
AU (1) AU659668B2 (sh)
BG (1) BG61693B1 (sh)
CA (2) CA2682254C (sh)
CZ (1) CZ283765B6 (sh)
DE (2) DE69232845T2 (sh)
DK (2) DK0526253T3 (sh)
EE (1) EE03002B1 (sh)
EG (1) EG20193A (sh)
ES (2) ES2335968T3 (sh)
FI (1) FI940435A0 (sh)
GB (1) GB9116601D0 (sh)
GE (1) GEP20002094B (sh)
HK (2) HK1008672A1 (sh)
HN (1) HN1997000118A (sh)
HU (2) HUT70030A (sh)
IL (1) IL102616A (sh)
MA (1) MA22919A1 (sh)
MD (1) MD1434C2 (sh)
MX (1) MX9204474A (sh)
NO (3) NO300842B1 (sh)
NZ (1) NZ243637A (sh)
OA (1) OA09883A (sh)
PH (1) PH30983A (sh)
PT (2) PT526253E (sh)
RS (1) RS49993B (sh)
RU (1) RU2126405C1 (sh)
SG (1) SG68541A1 (sh)
SK (1) SK280131B6 (sh)
TJ (1) TJ244R3 (sh)
TN (1) TNSN92070A1 (sh)
TW (2) TW366347B (sh)
WO (1) WO1993003027A1 (sh)
YU (1) YU49259B (sh)
ZA (1) ZA925668B (sh)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5728575A (en) * 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6812233B1 (en) * 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
GB9311709D0 (en) * 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
CA2171550C (en) 1993-09-10 2008-08-26 Raymond F. Schinazi Nucleosides with anti-hepatitis b virus activity
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
GB9506644D0 (en) * 1995-03-31 1995-05-24 Wellcome Found Preparation of nucleoside analogues
ES2276404T3 (es) 1995-06-07 2007-06-16 Emory University Nucleosidos con actividad antivirus de la hepatitis-b.
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
WO1998041522A1 (en) 1997-03-19 1998-09-24 Emory University Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides
AU6898498A (en) 1997-04-07 1998-10-30 Triangle Pharmaceuticals, Inc. Use of mkc-442 in combination with other antiviral agents
ES2232169T3 (es) 1998-08-12 2005-05-16 Gilead Sciences, Inc. Procedimiento de fabricacion de nucleosidos de 1,3-oxatiolano.
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
ATE408410T1 (de) * 1998-11-02 2008-10-15 Gilead Sciences Inc Kombinationstherapie zur behandlung von hepatitis b infektionen
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
DK1284720T3 (da) * 2000-03-29 2007-01-15 Univ Georgetown L-FMAU til behandling af hepatitis delta-virusinfektion
CA2308559C (en) 2000-05-16 2005-07-26 Brantford Chemicals Inc. 1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues
AU2008202336B2 (en) * 2001-03-01 2011-11-10 Abbvie Inc. Polymorphic and other crystalline forms of cis-FTC
CA2788498C (en) * 2001-03-01 2016-02-16 Gilead Sciences, Inc. Polymorphic and other crystalline forms of cis-ftc
AU2002364160A1 (en) * 2001-12-14 2003-06-30 Pharmasset Ltd. Preparation of intermediates useful in the synthesis of antiviral nucleosides
DE602004014470D1 (de) 2003-01-14 2008-07-31 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
ITMI20030578A1 (it) * 2003-03-24 2004-09-25 Clariant Lsm Italia Spa Processo ed intermedi per la preparazione di emtricitabina
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CN100360528C (zh) * 2005-08-31 2008-01-09 四川大学 4-氨基-1-(2-羟甲基-1,3-氧硫杂环戊烷-5-基)-2(1h)-嘧啶酮的制备方法
WO2007077505A2 (en) * 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited Crystalline l-menthyl (2r, 5s)-5-(4-amino-5-fluoro-2-oxo-2h-pyrimidin-1-yl)[1, 3]oxathiolan-2-carboxylate and process for preparation thereof
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
NZ593647A (en) 2008-12-23 2013-08-30 Gilead Pharmasset Llc Synthesis of purine nucleosides
MX2011006891A (es) * 2008-12-23 2011-10-06 Pharmasset Inc Fosforamidatos de nucleosidos.
EP2376514A2 (en) * 2008-12-23 2011-10-19 Pharmasset, Inc. Nucleoside analogs
EP2414507B1 (en) 2009-04-03 2014-07-02 Medical Research Council Mutants of activation-induced cytidine deaminase (aid) and methods of use
EP2377862A1 (en) 2010-03-29 2011-10-19 Esteve Química, S.A. Process for obtaining emtricitabine
AU2011235112B2 (en) 2010-03-31 2015-07-09 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP3449994A1 (en) 2012-01-10 2019-03-06 C.C. Jensen A/S System for cleaning degraded oil
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
DE2950317A1 (de) * 1979-12-14 1981-06-19 Agfa-Gevaert Ag, 5090 Leverkusen Elektrothermographische vorrichtung
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
HU226137B1 (en) * 1989-02-08 2008-05-28 Shire Canada Inc Process for preparing substituted 1,3-oxathiolanes with antiviral properties
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
WO1992010496A1 (en) * 1990-12-05 1992-06-25 University Of Georgia Research Foundation, Inc. ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it
AU662130B2 (en) * 1991-03-06 1995-08-24 Emory University Use of 5-fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis B
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues

Also Published As

Publication number Publication date
IL102616A0 (en) 1993-01-14
NZ243637A (en) 1995-03-28
ATE227720T1 (de) 2002-11-15
CZ20394A3 (en) 1994-07-13
CN101066970A (zh) 2007-11-07
AU2340892A (en) 1993-03-02
ATE448787T1 (de) 2009-12-15
GB9116601D0 (en) 1991-09-18
YU74992A (sh) 1995-12-04
CA2114221C (en) 2009-12-22
OA09883A (en) 1994-09-15
BG98616A (bg) 1995-03-31
US5538975A (en) 1996-07-23
NO300842B1 (no) 1997-08-04
CN1034810C (zh) 1997-05-07
PH30983A (en) 1997-12-23
EG20193A (en) 1997-10-30
PT1155695E (pt) 2010-02-02
US5618820A (en) 1997-04-08
CN101074228A (zh) 2007-11-21
CN1074924C (zh) 2001-11-21
GEP20002094B (en) 2000-05-10
EP1155695A1 (en) 2001-11-21
HN1997000118A (es) 1999-11-12
EP0526253A1 (en) 1993-02-03
NO2005017I2 (no) 2007-10-01
ZA925668B (en) 1993-04-28
DE69233776D1 (de) 2009-12-31
NO2005017I1 (no) 2005-09-05
ES2186667T3 (es) 2003-05-16
TJ244R3 (en) 1999-11-24
MX9204474A (es) 1993-12-01
NO940322L (no) 1994-03-21
DK0526253T3 (da) 2003-03-17
RS49993B (sr) 2008-09-29
CN1302612A (zh) 2001-07-11
HU211333A9 (en) 1995-11-28
MD950114A (en) 1996-06-28
AP9200414A0 (en) 1992-07-31
EE03002B1 (et) 1997-06-16
FI940435A (fi) 1994-01-28
CZ283765B6 (cs) 1998-06-17
MD1434C2 (ro) 2000-12-31
FI940435A0 (fi) 1994-01-28
AP321A (en) 1994-02-28
HK1008672A1 (en) 1999-05-14
CN1070191A (zh) 1993-03-24
DK1155695T3 (da) 2010-04-06
WO1993003027A1 (en) 1993-02-18
EP1155695B1 (en) 2009-11-18
SK10494A3 (en) 1994-12-07
DE69232845D1 (de) 2002-12-19
NO2008009I1 (no) 2008-06-30
CA2114221A1 (en) 1993-02-18
HU9400285D0 (en) 1994-05-30
TWI232217B (en) 2005-05-11
JPH07500317A (ja) 1995-01-12
IL102616A (en) 1996-10-31
MD1434B2 (en) 2000-03-31
RU2126405C1 (ru) 1999-02-20
NO940322D0 (no) 1994-01-31
PT526253E (pt) 2003-03-31
TNSN92070A1 (fr) 1993-06-08
CN1132073A (zh) 1996-10-02
AU659668B2 (en) 1995-05-25
KR100242454B1 (ko) 2000-03-02
CN100542535C (zh) 2009-09-23
CA2682254C (en) 2012-02-21
SG68541A1 (en) 1999-11-16
HUT70030A (en) 1995-09-28
CA2682254A1 (en) 1993-02-18
DE69232845T2 (de) 2003-04-24
ES2335968T3 (es) 2010-04-07
SK280131B6 (sk) 1999-08-06
BG61693B1 (bg) 1998-03-31
YU49259B (sh) 2004-12-31
TW366347B (en) 1999-08-11
EP0526253B1 (en) 2002-11-13
MA22919A1 (fr) 1993-04-01
JP2960778B2 (ja) 1999-10-12
HK1038189A1 (en) 2002-03-08

Similar Documents

Publication Publication Date Title
YU72303A (sh) Postupak za dobijanje (-)-4-amino-5-fluoro-1- (2-hiroksimetil-1,3-oksatiolan-5-il)-(1h)-pirimidin-2-ona
UA39166C2 (uk) Похідні n-гідроксисечовини, що є інгібіторами ліпоксигенази у ссавців, спосіб їх одержання і спосіб інгібування ліпоксигенази у ссавців
BR9711135A (pt) Composto composi-Æo farmac-utica utiliza-Æo de um composto e processos para prepara-Æo de um composto e para inibi-Æo de Äxido-equaleno ciclase num animal de sangue quente requerendo um tal tratamento
BG103518A (en) 2-(purin-9-yl)tetrahydrofuran-3,4-diol derivatives
IE840302L (en) 3-(5-aminopentyl)amino-1-benzazepin-2-one-1-alkanoic acids.
AU3181395A (en) Phenyl xanthine derivatives
GR3017996T3 (en) 17-g(b)-SUBSTITUTED-4-AZA-5-g(a)-ANDROSTAN-3-ONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION.
HUP9702345A2 (hu) 3-Hidroxi-piridin-2-karbonsav-amid-észter-származékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk
BG103000A (en) Compositions for single daily dosage in the treatment of cyclooxygenase-2-dependent diseases
EP0119161A3 (en) Benzazoquinone and benzazoninone derivatives, process for their preparation, their pharmaceutical preparations as well as their therapeutic use
MY106202A (en) Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof.
CA2094702A1 (en) Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
HUP0001922A2 (hu) Pirazolo[4,3-c]-piridin származékok, ezeket tartalmazó inzulinrezisztencia elleni gyógyszerkészítmények, intermedierek és eljárás előállításukra
CA2094703A1 (en) Substituted piperazines as central nervous system agents
CA2314154A1 (en) Azepine or larger medium ring derivatives and their use as pharmaceuticals
AU576386B2 (en) 1h-indol-3-yl containing 1,3-dimethyl-1h-purine-2,6-diones
HK1018783A1 (en) BENZO[C]QUINOLIZINE DERIVATIVES, THEIR PREPARATION AND USE AS 5 α-REDUCTASES INHIBITORS
MY107354A (en) Substituted cyclohexenes as central nervous system agents
AU567018B2 (en) Prazosin-pirbuterol combination for bronchoduation
HU886767D0 (en) Process for the preparation of new 20,21-dinor-eburnamenine derivatives, new intermediates thereof, as well as pharmaceutical compositions containing said compounds as active ingredients
AU579196B2 (en) 4-Oxo-piridol(2,3-d)pyrimidine derivatives, process for their preparation and pharmaceutical compositions containing them
GR3033649T3 (en) Growth factor compositions, preparation and use.
AU5608790A (en) New pyrrolidone derivatives, the process for their preparation and the pharmaceutical compositions containing them
MA19881A1 (fr) Procede de preparation de derives de spiro (2h-1,4-benzodioxepine-3 (5h) 4'-piperidine et -3'-pyrrolidine).
MX9703610A (es) Nuevas (5,6)-heteroaril condensado-pirimidin-4-onas 2,3 disustituidas.